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Aims: Oxidative stress and neurohumoral factors play important role in the development of hypertension-
induced vascular remodeling, likely by disregulating kinase cascades and transcription factors. Oxidative stress
activates poly(ADP-ribose)-polymerase (PARP-1), which promotes inﬂammation and cell death. We assumed
that inhibition of PARP-1 reduces the hypertension-induced adverse vascular changes. This hypothesis was
tested in spontaneously hypertensive rats (SHR).
Methods and results: Ten-week-old male SHRs and wild-type rats received or not 5 mg/kg/day L-2286 (a water-
soluble PARP-inhibitor) for 32 weeks, then morphological and functional parameters were determined in their
aortas. L-2286 did not affect the blood pressure in any of the animal groups measured with tail-cuff method.
Arterial stiffness index increased in untreated SHRs compared to untreated Wistar rats, which was attenuated
by L-2286 treatment. Electron and light microscopy of aortas showed prominent collagen deposition, elevation
of oxidative stress markers and increased PARP activity in SHR, which were attenuated by PARP-inhibition.
L-2286 treatment decreased also the hypertension-activated mitochondrial cell death pathway, characterized
by the nuclear translocation of AIF. Hypertension activated all three branches ofMAP-kinases. L-2286 attenuated
these changes by inducing the expression of MAPK phosphatase-1 and by activating the cytoprotective PI-3-
kinase/Akt pathway. Hypertension activated nuclear factor-kappaB, which was prevented by PARP-inhibition
via activating its nuclear export.
Conclusion: PARP-inhibition has signiﬁcant vasoprotective effects against hypertension-induced vascular remod-
eling. Therefore, PARP-1 can be a novel therapeutic drug target for preventing hypertension-induced vascular re-
modeling in a group of patients, in whom lowering the blood pressure to optimal range is harmful or causes
intolerable side effects.© 2014 Elsevier B.V. All rights reserved.cing factor; ASI, Aortic stiffness index; AP-1, activator protein 1; ASK1, apoptosis signal-regulating kinase 1; Crm1, chromosome
iastolic blood pressure; DD, diastolic diameter; ERK, extracellular signal regulated kinase; GSK-3β, glycogen synthase kinase 3; 4-
APK, mitogen-activated protein kinase; p38 MAPK, p38 mitogen-activated protein kinase; MKP-1, MAP kinase phosphatase-1;
-κB, nuclear factor kappaB; PAR, poly-ADP ribosylation; PARP-1, poly(ADP-ribose)polymerase-1; PBS, phosphate buffered saline;
inase C; ROS, reactive oxygen species; SBP, systolic blood pressure; SD, systolic diameter; SEM, standard error of the mean; SHR,
nd activator of transcription; TGF-β1, transforming growth factor beta 1; VEGF, vascular endothelial growth factor; WKY, Wistar
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Hypertension is a major public health problem both in middle-aged
and elderly people. It is both a complex disease and an important risk
factor for other cardiovascular outcomes, such as sudden death, stroke,
myocardial infarction, heart failure, and renal diseases [1]. Unfortunate-
ly, the control of arterial hypertension is far from optimal and has
improved only minimally over the last decades [1]. Side effects of
antihypertensive drugs, complaints due to their blood pressure
lowering effect and inadequate compliance are the key factors in the
background of inadequate control of hypertension [1,2]. Moreover
lowering blood pressure to the optimal range can be harmful in elderly
patients [3,4].
The spontaneously hypertensive rat (SHR)model is a suitablemodel
for studying the development and consequences of hypertension. The
development of vascular remodeling is an early and important conse-
quence of hypertension. Vascular remodeling is mainly characterized
by vascular smooth muscle cell hypertrophy and increased production
of extracellular matrix [5]. Remodeling is initially an adaptive process
that evolves in response to long-term pressure overload, but ﬁnally it
can contribute to the development of hypertensive target organ
damages [3–5].
By now it has been well established that oxidative stress has a caus-
ative role in the development of hypertensive vascular complications
and vascular remodeling [5,6]. ROS are important in regulating
endothelial function and vascular tone, and are implicated in endotheli-
al dysfunction, inﬂammation, hypertrophy, apoptosis, migration, ﬁbro-
sis and angiogenesis [7,8]. ROS-induced injury of the ion channels and
the decreased amount of high energy phosphates can result in profound
alterations in smooth muscle cell calcium homeostasis leading to in-
creased smooth muscle cell proliferation and contractility [9]. The in-
creased vascular tensile stress, the oxidative stress and neurohumoral
factors in hypertension equally inﬂuence the activity of downstream
signaling molecules [10,11]. Oxidative stress induced signaling such as
activation of MAPKs, PKC isoenzymes, NF-κB, AP-1 and STAT can signif-
icantly contribute to the development of hypertension induced vascular
remodeling [10,12–14]. Therefore, attenuating oxidative stress, or
inhibiting these pathways may present an alternative way to protect
the vasculature from hypertension induced damages [5,14]. Using
antioxidants did not produce the expected results [5,15] necessitating
speciﬁc inhibition of ROS-induced processes that lead to signaling
anomalies.
Oxidative stress induced by hypertension can lead to single stranded
DNA breaks and poly(ADP-ribose)polymerase-1 (PARP-1) activation
[16,17]. Because of its high copy number, overactivation of the enzyme
can induce NAD+ and thereby ATP depletion leading to necrotic cell
death [18–20], or trigger apoptosis by promoting the release of mito-
chondrial pro-apoptotic proteins, such as AIF and endonuclease G [22,
23]. In addition, PARP activation by promoting mitochondrial damage
[21] can further induce ROS production, elevated intracellular Ca2+
and destabilize the mitochondrial membrane system leading to mito-
chondrial permeability transition and cell death [20,22,34]. Further-
more, PARP activation can activate NF-κB and AP-1 transcription
factors [24–26], which can signiﬁcantly contribute to cardiovascular re-
modeling [27,28]. Therefore, it is likely that inhibition of PARP can favor-
ably inﬂuence intracellular signaling during hypertension, which can
contribute to the reduction of vascular remodeling [29]. Activation of
PARP was demonstrated within vascular endothelial and smooth mus-
cle cells of large atherosclerotic arteries [30,31]. Inhibition of PARP, in
turn, had a positive effect on vascular dysfunction associated with
advanced aging, diabetes or hypercholesterolemia [7,8,30,31]. Further-
more, as we found previously, inhibition of PARP by L-2286 [32] inﬂu-
enced beneﬁcially the signaling pathways in hypertension induced
cardiac remodeling [28].
However, there is no available data concerning the potential role
of PARP activation in the pathogenesis of hypertension-inducedvascular dysfunction and remodeling in vivo. On the basis of
the aforementioned, we hypothesized that the administration of
L-2286 in hypertensive animals decreases oxidative stress, modu-
lates signaling pathways (PI-3K-Akt, MAP kinases) and attenuates
NF-κB activation, thereby reduces the hypertension-induced adverse
vascular changes. In the present study we tested this hypothesis by
using spontaneously hypertensive rats.
2. Methods
2.1. Animal model and noninvasive blood pressure measurement
Ten-week-old male SHR rats obtained from Charles River Laborato-
ries (Budapest, Hungary) were randomly divided into two groups.
One group received no treatment (SHR-C, n = 10), whereas the other
group (SHR-L, n = 10) received 5 mg/kg/day 2-[(2-piperidine-1-
ylethyl)thio]quinazolin-4(3H)-one (L-2286), a water-soluble PARP
inhibitor [32] for 32 weeks. The third group was an age-matched nor-
motensive control group (WKY-C, n = 10, Charles River Laboratories,
Budapest, Hungary). The fourth was a normotensive age-matched
group receiving 5 mg/kg/day L-2286 treatment (WKY-L, n = 10). The
dose of L-2286 was based on our previous results with this PARP inhib-
itor [28,31]. According to these data, L-2286 can exert protective effects
against oxidative cell damage in concentration of 10 μM. The serum
concentration of L-2286 in the applied dose (5 mg/kg/day) with an es-
timated average bioavailability is approximately 10 μM in rats. L-2286
was dissolved in drinking water on the basis of preliminary data about
the volume of daily consumption, but the water was provided ad
libitum throughout the experiment. Before the administration of
L-2286 and at the end of the 32-week treatment period, ultrasound
imaging was performed on each animal. Noninvasive blood pressure
measurement was carried out in every fourth week from the beginning
of the study using the tail-cuffmethod (Hatteras SC 1000 Single Channel
System) [33]. At the end of the study, animals were euthanized with an
overdose of ketamine hydrochloride intraperitoneally and heparinized
with sodium heparin (100 IU/rat i.p., Biochemie GmbH, Kundl,
Austria). Aortaswere removed under anOlympus operationmicroscope
andwere freeze-clamped and stored at−70 °C or ﬁxed in 10% formalin.
The investigation conforms to the Guide for the Care and Use of
Laboratory Animals published by the US National Institutes of Health
(NIH Publication No. 85-23, revised 1996), and was approved by the
Animal Research Review Committee of the University of Pecs Medical
School.
2.2. Transthoracic echocardiography
At baseline, all animals were examined by ultrasound to exclude rats
with any abnormalities. Two-dimensional ultrasound was performed
under inhalation anesthesia at the beginning of the experiment and
on the day of sacriﬁce. Rats were lightly anesthetized with a mixture
of 1.5% isoﬂurane and 98.5% oxygen. The necks and the upper part of
the chests of the animals were shaved, acoustic coupling gel was
applied, and warming pad was used to maintain normothermia. ASI
were measured by a VEVO 770 high-resolution ultrasound imaging
system (VisualSonics, Toronto, Canada) — equipped with a 40 MHz
transducer. Aortic elastic property was calculated according to a previ-
ously proposed and evaluated formula [34]: (ASI) = ln(SBP/DBP) ×
DD/(SD− DD).
2.3. Immunohistochemistry and confocal laser scanning ﬂuorescence
microscopy
Aortic segments separated for immunohistochemical and immunﬂuo-
rescence processing were ﬁxed immediately after excision in buffered
paraformaldehyde solution (4%) for 1 day. Fivemircometer thick sections
were cut.
Fig. 1. SBP values of normotensive (WKY-C, WKY-L) and hypertensive (SHR-C, SHR-L)
rats. Values are means ± SEM. *p b 0.05 (WKY groups vs. SHR groups).
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primary antibody used for the stainings was a monoclonal anti-4-HNE
antibody (kind gift from Imunology and Biotechnology Department,
Pecs, Hungary). Binding was visualized with biotinylated secondary
antibody followed by the avidin–biotin-peroxidase detection system
(Universal Vectastain ABC Elite Kit, Vector Laboratories, Burlingame,
CA) using DAB as chromogen. Progress of the immunoreaction was
monitored under a light microscope and the reaction was stopped by
the removal of DAB. Some slices were stained with Masson's trichrome
staining to detect the interstitial ﬁbrosis as described earlier [35] and
quantiﬁed with the NIH Image J analyzer system. All histological
samples were examined by an investigator in a blinded fashion.
Immuno-ﬂuorescencewas performed for AIF, NF-κB andMKP-1. Pri-
mary antibodies used for the staining were polyclonal rabbit antibodies
(Cell Signaling Technology, Kvalitex Ltd. and Santa Cruz Biotechnology,
respectively). As secondary antibody, donkey-anti-rabbit antibody
(R and D Systems, NorthernLights, ﬂuorochrome-labeled antibody;
1:200)was used. The stainings were ﬁnished by Hoechst (Sigma) coun-
terstain. Sectionswere examined using a confocal laser scanmicroscope
(Olympus Fluoview 1000). Recording for Rhodamine Red™-X (excited
with the green laser, Helium-Neon) was followed by recording for
Hoechst with a 405 nm laser.
2.4. Western blot analysis
Aortic segments were homogenized in ice-cold 50 mM Tris-buffer,
pH 8.0 (containing protease inhibitor cocktail 1:1000, and 50mM sodi-
um vanadate, Sigma-Aldrich Co., Budapest) and harvested in 2× con-
centrated SDS–polyacrylamide gel electrophoresis sample buffer.
Proteins were separated on 10 or 12% SDS–polyacrylamide gels. After
blocking (2 h with 3% non-fat milk in Tris-buffered saline), membranes
were probed overnight at 4 °Cwith antibodies recognizing the following
antigenes: phospho-speciﬁc Akt-1/protein kinase B-alphaSer473
(1:1000), anti-actin (1:10,000), phospho-speciﬁc extracellular signal
regulated kinase (ERK 1/2)Thr183-Tyr185 (1:1000), phosphorylated p38
mitogen-activated protein kinaseThr180-Gly-Tyr182 (p38 MAPK) (1:1000),
phospho-speciﬁc c-Jun N-terminal kinase (JNK) (1:1000), phosphory-
lated MAP kinase phosphatase-1Ser359 (MKP-1) anti poly(ADP-ribose)
(anti-PAR, 1:5000), anti-NF-κBp105/p50 (1:1000). Antibodies were
purchased from R and D Systems, Biomedika Ltd., Hungary, except for
anti-actin, which was bought from Sigma-Aldrich Co, Budapest,
Hungary, anti-PAR, which was bought from Alexis Biotechnology,
London, UK and anti-NF-κB which was purchased from Cell Signaling,
Kvalitex Ltd., Hungary. Membranes were washed six times for 5 min
in Tris-buffered saline (pH 7.5) containing 0.2% Tween (TBST) before
the addition of goat anti-rabbit horseradish peroxidase-conjugated
secondary antibody (1:3000 dilution, Bio-Rad, Budapest, Hungary).
The antibody–antigen complexes were visualized by means of
enhanced chemiluminescence. After scanning, results were quantiﬁed
by NIH Image J program.
2.5. Electron microscopy
For electronmicroscopy, blocks were prepared from the same aortic
segments that were used for light microscopy. 1-mm long blocks were
cut from the aorta and were ﬁxed in 4% buffered formaldehyde mixed
with a 2,5% glutaraldehyde solution for 24 h at 4 °C. After washing in
phosphate buffer, the samples were ﬁxed in 1% osmium tetroxide in
0.1 M PBS for 35 min. After that, the samples were washed in buffer
several times for 10 min each and dehydrated in an ascending ethanol
series, including a step of uranyl acetate (1%) solution in 70% ethanol
to increase the contrast. Dehydrated blocks were transferred to propyl-
ene oxide before being placed into aluminum-foil boats containing
Durcupan resin (Sigma) and then embedded in gelatin capsules
containing Durcupan. The blocks were placed in thermostat for 48 h at
56 °C. From the embedded blocks, 1 micrometer thick semithin andserial ultrathin sections (70 nm) were cut with a Leica ultramicrotome,
and mounted either on mesh, or on Collodion-coated (Parlodion,
Electron Microscopy Sciences, Fort Washington, PA) single-slot, copper
grids. Additional contrast was provided to these sections with uranyl
acetate and lead citrate solutions, and they were examined with a
JEOL 1200EX-II electron microscope [36].
2.6. Statistical analysis
All data are expressed as mean ± SEM. Comparisons between two
groups were made using independent sample t-test, multigroup com-
parisons were made by one-way ANOVA test (SPSS for Windows
11.0). For post hoc comparison, the Bonferroni test was applied. Values
of p b 0.05 were considered statistically signiﬁcant.
3. Results
3.1. Effect of L-2286 treatment on systolic blood pressure
During the 32-week treatment period, systolic blood pressure of
hypertensive (SHR-C, SHR-L) rats was signiﬁcantly higher than that of
normotensive (WKY) rats (at the age of 10 weeks SHR: 180 ±
5.6 mm Hg, WKY: 130 ± 5.4 mm Hg, at the age of 42 weeks SHR-C:
230 ± 6.3, SHR-L: 225 ± 2.4 mm Hg, WKY-C: 130 ± 5.4, WKY-L:
135 ± 5.5 mm Hg, p b 0.05; SHR-C vs. WKY-C, SHR-C vs. WKY-L
p b 0.05; SHR-L vs.WKY-C, SHR-L vs.WKY-L p b 0.05). L-2286 treatment
did not alter systolic blood pressure of SHR animals during the 32-week
treatment period (Fig. 1).
3.2. Effect of L-2286 administration on aortic stiffness
At the beginning of the study there was no signiﬁcant difference
between the arterial stiffness index (ASI) of the normotensive (WKY)
and the hypertensive (SHR) animals (ASI: WKY: 3.79 ± 0.46, SHR:
3.86 ± 0.41). ASI of normotensive animals did not change during the
32-week-long treatment period. However in hypertensive rats ASI
values almost doubled by the end of the study period (at the age of
42 weeks WKY-C: 4.1 ± 0.1, WKY-L: 3.98 ± 0.2, SHR-C: 5.8 ± 0.3,
SHR-L: 4.3 ± 0.4 p b 0.05; SHR-C vs. WKY-C, SHR-C vs. WKY-L
p b 0.05). L-2286 treatment decreased signiﬁcantly the hypertension-
induced elevation of aortic stiffness (SHR-L vs. SHR-C, p b 0.05; SHR-L
vs. WKY-C, SHR-L vs. WKY-L p b 0.05) (Fig. 2).
Fig. 2. ASI of aorta of normotensive (WKY-C, WKY-L) and hypertensive (SHR-C, SHR-L)
rats. Values are means ± SEM. #p b 0.05 (SHR-C vs. WKY-C, WKY-L, SHR-L), §p b 0.05
(SHR-L vs. WKY-C, WKY-L).
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Masson's trichrome stainingwas used to evaluate the degree of vascu-
lar ﬁbrosis. The highest collagen content was observed in the aortas of
non-treated hypertensive rats (SHR-C) (WKY-C: 19.22 ± 0.8%, WKY-L:
19.55 ± 0.73%, SHR-C: 27.62 ± 1.45%, SHR-L: 21.24 ± 0.63%, p b 0.05;
SHR-C vs. WKY-C, SHR-C vs. WKY-L, p b 0.05). The extent of vascularFig. 3. Effect of L-2286 treatment on the interstitial collagen deposition. Representative histologi
B: aorta ofWKY-L, C: aorta of SHR-C, D: aorta of SHR-L. *p b 0.05 SHR-C vs.WKY-L, SHR-L, #p b 0
wall of 42week-old animals. Lu: lumen, bm: basalmembrane, sm: smoothmuscle cell, el: lamin
of SHR-C, I: aorta of SHR-L.ﬁbrosis was signiﬁcantly moderated by the L-2286 treatment (SHR-C vs.
SHR-L, p b 0.05; SHR-L vs.WKY-C, SHR-L vs.WKY-L p b 0.05) (Fig. 3A–D).
3.4. Ultrastructural examination of aortic wall
Electronmicroscopic examinations showed intact architecture of aor-
tic wall isolated fromWKY rats (Fig. 3). However, in untreated SHR ani-
mals (SHR-C) the chronic presence of elevated blood pressure resulted
in serious alterations in the structure of aortic wall. The endothelial cells
were activated, their nuclei were segmented, unfolded and their cyto-
plasmwas extremelywidened (Fig. 3G andH). The internal elastic lamina
(IEL) was periodically interrupted and cytoplasmic processes of medial
smooth muscle cells were protruded through the intimal lesions into
the subendothelium and into the lumen (Fig. 3H). The subendothelial
space increased and an extreme amount of collagen bundles was pro-
duced by activatedﬁbroblasts causing the damage of the basalmembrane
(Fig. 3G and H). “Mushroom-like” formations containing collagen ﬁbers
broke through the interendothelial spaces into the lumen. Smooth-
muscle cells appeared very frequently producing elastic ﬁbers. These
ﬁbers grew in various directions destroying normal layers (Fig. 3H).
Due to the treatment with the PARP-inhibitor L-2286 (SHR-L), a
signiﬁcantly better morphology of vascular wall could be observed.
Although activated nuclei in the endothelial layer could be seen, the con-
tinuity of this layer remained intact. The amount of collagen bundles and
elasticﬁberswas also reduced in the SHR-L group compared to that of the
SHR-C animals and therefore the basal membrane was not damaged by
collagen ﬁbers and by smooth muscle cells. Thus, pharmacologicalc sections, stainedwithMasson's trichrome (n=4) (scale bar 100 μm). A: aorta ofWKY-C,
.05 SHR-L vs.WKY-C,WKY-L. E–I. Representative electronmicroscopic sections from aortic
a elastica interna, e: endothel. E: aorta ofWKY, F: aorta ofWKY, G: aorta of SHR-C, H: aorta
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hypertension-induced vascular remodeling due to its favorable effect on
vascular ﬁbroblast and on smooth muscle cell function (Fig. 3I).3.5. Effect of L-2286 administration on poly(ADP-ribosyl)ations in aortas
To determinewhether or not the administered PARP-inhibitor treat-
ment was effective, we detected the poly(ADP-ribosyl)ation of proteins
in vascular samples.Western blot analysis of large arteries revealed that
ADP-ribosylation of proteins was the highest in the SHR-C group. This
elevation was signiﬁcantly decreased by L-2286 treatment (p b 0.05)
(Fig. 4).Fig. 4. Effect of L-2286 treatment on the phosphorylation state of Akt-1Ser473, JNKThr183-Tyr18
C, WKY-L) and hypertensive (SHR-C, SHR-L) rats. Representative Western blot analysis
phosphorylation, anti-PAR and densitometric evaluations are shown (n = 4). Actin is sho
#p b 0.05 SHR-L vs. SHR-C, +p b 0.05 WKY-L vs. WKY-C.3.6. Effect of PARP inhibition on an oxidative stress marker and on nuclear
translocation of AIF
For veriﬁcation of oxidative stress the production of 4-HNE, a lipid
peroxidation product was investigated (WKY-C: 11.98 ± 1.02%, WKY-
L: 13.76 ± 2.53%, SHR-C: 29.26 ± 1.61%, SHR-L: 13.9 ± 3.29%) (Fig. 5).
Almost negative immunostaining for 4-HNE was observed in aortic
sections of control groups (Fig. 5A and B). In contrast, in hypertensive an-
imals (SHR-C) immunostaining was notably increased (SHR-C vs. WKY-
C, SHR-C vs. WKY-L p b 0.05) (Fig. 5C), which was attenuated by L-2286
treatment (SHR-L), (SHR-C vs. SHR-L p b 0.05) (Fig. 5D).
In normotensive animals (WKY-C and WKY-L) the apoptosis-
inducing factor (AIF) could only be found in the cytoplasm of cells5, ERK 1/2Thr183-Tyr185 and p38-MAPKThr180-Gly-Tyr182 in aortas of normotensive (WKY-
of Akt-1Ser473, JNKThr183-Tyr185, ERK 1/2Thr183-Tyr185 and p38-MAPKThr180-Gly-Tyr182
wn as loading control. Values are means ± SEM. *p b 0.05 SHR-C vs. WKY-C, WKY-L,
Fig. 5. Effect of L-2286 treatment on the hypertension-induced oxidative stress. A–D.: Representative immunohistochemical stainings for 4-hydroxynonenal (4-HNE, brown staining) in
the aorticwall of normotensive (WKY-C,WKY-L) and hypertensive (SHR-C, SHR-L) animals. A: aorta ofWKY-C, B: aorta ofWKY-L, C: aorta of SHR-C, D: aorta of SHR-L. Values aremeans±
SEM. *p b 0.05 SHR-C vs. WKY-C, WKY-L, #p b 0.05 SHR-L vs. SHR-C.
940 K. Magyar et al. / Biochimica et Biophysica Acta 1842 (2014) 935–944(Fig. 6A and B). In the SHR-C group we found nuclear translocation of
AIF, which was signiﬁcantly decreased in the SHR-L group due to the
PARP inhibition by L-2286 treatment (p b 0.05) (Fig. 6C and D).3.7. Effect of PARP inhibition on theMKP-1 expression and NF-κB activation
Oxidative stress elicited an enhanced expression of MKP-1, which
was also evident in the vessel samples because MKP-1 activity was
more elevated in SHR-C than in WKY animals as shown by Western
blotting (SHR-C vs.WKY-C, SHR-C vs.WKY-L, p b 0.05) and immunoﬂu-
orescence. Inhibition of PARP enzymewith L-2286 further increased the
phosphorylation of MKP-1 in the aortas of hypertensive rats (SHR-L vs.
SHR-C p b 0.05, SHR-L vs. WKY-C, SHR-L vs. WKY-L p b 0.05) (Fig. 7).
In control animals NF-κB could be detected only in the cytoplasm of
cells.We also found thehypertension-induced nuclear transport and ac-
tivation of NF-κB which was signiﬁcantly diminished by L-2286 treat-
ment (Fig. 8). Elevated NF-κB activity was shown with Western
blotting in hypertensive animals (SHR-C vs. WKY-C, SHR-C vs. WKY-L
p b 0.05) which was attenuated by L-2286 treatment (SHR-C vs.
SHR-L p b 0.05, SHR-L vs. WKY-C, SHR-L vs. WKY-L p b 0.05) (Fig. 8).Fig. 6.A–D:Representativemerged confocal images of nuclear localisation of AIF. AIF immunore
(scale bar 10 μm) A: aorta of WKY-C, B: aorta of WKY-L, C: aorta of SHR-C, D: aorta of SHR-L.3.8. Effect of L-2286 treatment on the phosphorylation state of Akt-1 and
MAP kinases in aortas
Akt-1Ser473 was phosphorylated in 42-week-old WKY-C rats, but
its phosphorylation was even higher in the SHR-C group (p b 0.05),
which was further increased in SHR-L (p b 0.05) animals due to the
PARP inhibitor treatment. Phosphorylation of Akt-1Ser473 was also
increased in the WKY-L group compared to WKY-C rats (p b 0.05).
In case of MAPK kinases, the modest phosphorylation of the exam-
ined MAPKs – p38-MAPKThr180-Gly-Tyr182, JNK and ERK1/2Thr183-
Tyr185 – occurred in WKY rats (SHR-C vs. WKY-C, SHR-C vs. WKY-L
p b 0.05). The phosphorylation of p38-MAPKThr180-Gly-Tyr182, ERK1/
2Thr183-Tyr185 and JNK in SHR-C rats was the highest, and these
alterations were signiﬁcantly attenuated by the L-2286 treatment
(SHR-C vs. SHR-L p b 0.01) (Fig. 4).4. Discussion
In hypertensive patients, systolic blood pressure (SBP) and pulse
pressure are the dominant prognostic markers. The concept of “loweractivity (red) andHoechst nuclear staining (blue)were presented individually andmerged
Fig. 7. A: Effect of the L-2286 treatment on the phosphorylation state of MKP-1 in aortas of normotensive (WKY-C, WKY-L) and hypertensive (SHR-C, SHR-L) rats. Densitometric evalu-
ations are shown (n= 4). Actin is shown as loading control. Values aremeans± SEM. *p b 0.05 SHR-C vs. WKY-C, WKY-L SHR-L, #p b 0.05 SHR-L vs. WKY-C,WKY-L. B-E: Representative
merged confocal images of nuclear localization ofMKP-1.MKP-1 immunoreactivity (red) andHoechst nuclear staining (blue)were presentedmerged (scale bar 10 μm). B: aorta ofWKY-C,
C: aorta of WKY-L, D: aorta of SHR-C, E: aorta of SHR-L.
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epidemiological data from landmark studies such as MRFIT [37] and
UKPDS [38]. These studies showed that increasing levels of SBPwere as-
sociated with a higher risk of cerebro- and cardiovascular events [38].
The elevated intraluminal pressure causing cyclic circumferential
mechanical strain is the cardinal feature in the development of vascular
remodeling [40,41]. Vascular cells can sense changes in mechanical
signal and can transduce these alterations into biological response in a
process called mechanotransduction [39]. Therefore the most commonFig. 8.A: Effect of the L-2286 treatment on thephosphorylation state of NF-κB in aortas of normo
are shown (n=4). Actin is shown as loading control. Values aremeans±SEM. *p b 0.05 SHR-C
confocal images of nuclear localization of NF-κB. NF-κB immunoreactivity (red) andHoechst nu
of WKY-L, D: aorta of SHR-C, E: aorta of SHR-L.protective mechanism against the development of hypertensive vascu-
lar remodeling is the lowering of blood pressure. On the other hand, side
effects of antihypertensive drugs and complaints such as dizziness,
headache, fatigue due to the hypoperfusion resulting from lowering
the blood pressure are the key factors in the background of inadequate
hypertension control [2]. In order to optimize management of hyper-
tension, some recent efforts focus on protecting the vasculature from
hypertension induced vascular remodeling with or without lowering
the blood pressure [42].tensive (WKY-C,WKY-L) and hypertensive (SHR-C, SHR-L) rats. Densitometric evaluations
vs.WKY-C,WKY-L, SHR-L, #p b 0.05 SHR-L vs.WKY-C,WKY-L. B-E: Representativemerged
clear staining (blue)were presentedmerged (scale bar 10 μm). B: aorta ofWKY-C, C: aorta
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of hypertension and promising results in various experimental models
[43,44] antioxidants such as vitamins C and E, and β-carotene were
tried, however, they failed to have the anticipated clinical efﬁcacy [45,
46]. Therefore, to prevent hypertension induced remodeling the pre-
vention of harmful consequences of oxidative stress can be beneﬁcial.
In this study, we propose PARP-1 enzyme as a novel therapeutic target
to prevent hypertension induced vascular alterations, because PARP
enzyme is activated by ROS and can affect signaling pathways and
transcription factors pivotally involved in the pathomechanism of
remodeling [20].
It is well established that PARP inhibitors can prevent oxidative stress
induced tissue damage; they can favorably modulate PI-3-kinase/Akt-1
and MAP kinase pathways, and inhibit NF-κB activation [47,48]. In addi-
tion, although PARP inhibition did not have any antihypertensive effects
[28,49], it exerted signiﬁcant protection against the transition of hyper-
tensive cardiopathy to heart failure in SHRs [28]. In accordance with
these results, we found in the present study that chronic inhibition of
PARP with L-2286 did not decrease the blood pressure in SHR animals
(Fig. 1), but it decreased the hypertension induced remodeling of great
arteries. Remodeling is characterized by increased vascular wall thick-
ness, altered vascular tone, increased vascular contractility as well as
by the reduction of vascular compliance. Chronic elevated blood pressure
causes the thickening of the vascular wall and alters vascular elasticity.
As we found, the PARP-inhibitor L-2286 improved signiﬁcantly the
hypertension-induced increased arterial stiffness (Fig. 2). The thickness
and the elastic properties of vascular wall are determined primarily by
the amount of smooth muscle cells and by the amount of collagen con-
tent. The vascular collagen content was determined by transmission
electron microscopy (Fig. 3E–I) and by Masson's trichrome staining
(Fig. 3A and D). Both methods showed a very prominent increase of
vascular ﬁbrosis in non-treated SHR animals. Moreover, on electron mi-
croscopic pictures the invasibility of ﬁbrosis could also be seen, because
the collagen bundles damaged the basal membrane and broke into the
lumen. Pharmacological inhibition of nuclear PARP-1 caused a signiﬁcant
decrease in the process of ﬁbrotic remodeling and this treatment
protected the integrity of vascular structure, too.
Elevated ROS production was documented in hypertension which
triggers PARP-1 activation in various experimental models [50,51].
Completely in accordance with these results, we observed increased al-
dehyde by-product formation (Fig. 5) and elevated protein PARylation
(Fig. 3), indicating increased oxidative stress [50,52] and consequent
PARP activation in hypertensive animals. As it was expected, they all
were decreased by the PARP inhibitor treatment, because PARP-
inhibitors were demonstrated to decrease ROS-induced mitochondrial
ROS formation via their protective effect on the mitochondrial respira-
tory chain complexes [20,21,53]. It is well documented that activation
of the PI3K/Akt-1/GSK-3β cytoprotective pathway, and inhibition of
JNK and p-38 MAPK are substantially involved in the mitochondrial
protecting effect of PARP inhibition [21,48,54]. Accordingly, we found
elevated MAPK and Akt-1 activation in the aorta of SHR rats that was
inhibited and further activated by the L-2286 treatment, respectively
(Fig. 4). Akt-1 is one of the most important prosurvival intracellular
signal transduction factor [28,29] and can account for several protective
effects of L-2286 treatment. The activation of Akt-1 yields numerous
beneﬁcial consequences, e.g. its activation can also decrease the ROS
production through the inhibition of NADPH oxidases [50].
Hypertension induced impairment of mitochondrial integrity
results in the release of inter-membrane proteins including AIF and
its translocation to the nucleus. This process induces large-scale
chromatin fragmentation followed by caspase independent apopto-
tic cell death [55,56]. In accordance with these results, nuclear trans-
location of AIF increased signiﬁcantly in vascular smooth muscle
cells of untreated SHR animals, which was attenuated by L-2286
treatment (Fig. 6). AIF translocation [58] can be attenuated by de-
creased formation of PAR and by the activation of Akt-1. Blockingthe nuclear translocation of AIF can also positively inﬂuence vascular
remodeling through themodulation of proliferation andmigration of
vascular smooth muscle cells [22,57].
Activation of signal transductionmolecules and transcription factors
due to oxidative stress has other effects besides damagingmitochondria
in hypertension-induced mechanotransduction. MAP kinases (ERK-1/2,
p38-MAPK, JNK) and several PKC izoenzymes are activated in conse-
quence of vascular stretch induced oxidative stress. The importance of
MAP kinases was extensively studied in experimentalmodels of various
cardiovascular pathologies. We previously proved in cell culture that
PARP-1 inhibition resulted in the inactivation of these MAPKs through
the increased expression and enlarged cytoplasmic localization of
MAPK phosphatase-1 (MKP-1) [59]. We conﬁrmed this ﬁnding recently
in a much more complicated experimental model; in a chronic murine
model of hypertension. Accordingly, we found diminished MKP-1
expression and increased activation of p-38MAPK and JNK in hyperten-
sive rats, which changeswere reversed by the L-2286 treatment (Figs. 4
and 7). The increased MKP-1 expression and thereby the decreased
MAP kinase activities can be responsible for the diminished vascular
collagen accumulation observed in L-2286 treated SHRs. The decreased
phosphorylation state ofMAP kinases exerts protection against vascular
remodeling in these animals, because it can reduce the ﬁbrosis through
a TGF-β independent pathway [60,61]. Oxidative stress in hypertension
activates the transcription factor NF-κB and inhibits its export from nu-
cleus to cytoplasm by Crm1. NF-κB activation via AngII and p38-MAPK
can also increase the ﬁbrosis via a TGF-β1 dependent pathway [62,63]
and can enhance the production of inﬂammatory proteins that have
central role in the development of endothelial dysfunction and athero-
sclerosis [64,65]. In our experimentalmodelwe found increased nuclear
translocation of NF-κB in untreated SHR rats, which was diminished by
L-2286 treatment. In conclusion, pharmacological inhibition of PARP-1
enzyme exerted signiﬁcant protection against hypertensive vascular re-
modeling in spite of the lack of having any antihypertensive effect.
Therefore PARP can be a promising therapeutic target to prevent hyper-
tensive vascular complications even in those patients who do not reach
the target blood pressure because of complaints or because of side
effects caused by antihypertensive drug therapy. Our previous [28]
and present results can introduce a new concept into the treatment of
essential hypertension, namely to lower blood pressure to amore toler-
able level and to prevent target organ damages by PARP-inhibition.
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